相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2011)
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology ovarian cancer study group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
Gabriella Ferrandina et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
Ian A. Cree et al.
ANTI-CANCER DRUGS (2007)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer
G. P. Stathopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer
T. Le et al.
GYNECOLOGIC ONCOLOGY (2006)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma:: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
AJ González-Martín et al.
ANNALS OF ONCOLOGY (2005)
A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2005)
The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
T Kita et al.
GYNECOLOGIC ONCOLOGY (2004)
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
WT Huinink et al.
ANNALS OF ONCOLOGY (2004)
Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer
S Ghamande et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]
I Vergote et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2000)
Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials
GJS Rustin et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
MJ Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
